Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 13/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 11/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037872 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL7202429 | 0.89 | ENPP3 (0.35) | SMN1; SMN2POLBENPP3ENPP1ENPP2 | |
| SCHEMBL5036477 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5033793 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5037647 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5033727 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5036151 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5036686 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5042923 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9APOLBTDP1 | |
| SCHEMBL5036798 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | claimed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | SMN1; SMN2 2426/4885NPC1 3782/4885RAB9A 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.